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Sepsis is characterized by a dysregulated inflamma-
tory response to infection. Despite studies in mice,
the cellular and molecular basis of human sepsis re-
mains unclear and effective therapies are lacking.
Blood monocytes serve as the first line of host de-
fense and are equipped to recognize and respond
to infection by triggering an immune-inflammatory
response. However, the response of these cells in
human sepsis and their contribution to sepsis patho-
genesis is poorly understood. To investigate this, we
performed a transcriptomic, functional, and mecha-
nistic analysis of bloodmonocytes frompatients dur-
ing sepsis and after recovery. Our results revealed
the functional plasticity of monocytes during human
sepsis, wherein they transited from a pro-inflam-
matory to an immunosuppressive phenotype, while
enhancing protective functions like phagocytosis,
anti-microbial activity, and tissue remodeling. Mech-
anistically, hypoxia inducible factor-1a (HIF1a) medi-
ated this functional re-programming of monocytes,
revealing a potential mechanism for their therapeutic
targeting to regulate human sepsis.
INTRODUCTION
Sepsis is a complex pathology that arises from dysregulated
host inflammatory responses to systemic bacterial infection
(Hotchkiss et al., 2009). Human sepsis is a leading cause of
death in intensive care units (ICUs) worldwide. Yet, the immuno-
logical and molecular basis of this syndrome is poorly under-
stood. In the last 20 years, numerous therapeutic strategies to
ameliorate human sepsis have failed in clinical trials and reliable484 Immunity 42, 484–498, March 17, 2015 ª2015 Elsevier Inc.biomarkers for sepsis are still lacking (Focus on sepsis, 2012).
The reason for such a dismal scenario can be partially attributed
to the complex and dynamic nature of the condition, as well as
important species-specific differences in innate responses be-
tween mouse model systems and human patients (Schroder
et al., 2012; Seok et al., 2013).
In line with the dynamic nature of sepsis, two phases have
been recognized in this disease: an early inflammatory phase
and a late immunosuppressive phase (Biswas and Lopez-Col-
lazo, 2009; Hotchkiss et al., 2009). The early phase is character-
ized by leukocyte activation, cytokine storm, and a systemic
inflammatory response, while the later phase is characterized
by immunosuppression, leukocyte deactivation, increased risks
of secondary infection, and high mortality (Boomer et al., 2011;
Hotchkiss et al., 2009). The scenario might be evenmore compli-
cated with the overlapping co-existence of inflammatory and
immunosuppressive processes, as suggested by some (Adib-
Conquy and Cavaillon, 2009; Xiao et al., 2011). Further, contrast-
ing the common view that overt inflammation drives mortality in
sepsis, this response is often effectively controlled by standard
ICU practices, whereas recent evidence has emphasized how
immunosuppression might contribute to increasing mortality
risk in most sepsis patients (Boomer et al., 2011; Hotchkiss
et al., 2009; Pachot et al., 2006; Tang et al., 2010). However,
the lack of infection foci in sepsis patient organs and the
emerging role of immunometabolism and neurophysiological
mechanisms in organ dysfunction in sepsis reveal further
complexity (Deutschman and Tracey, 2014). Nonetheless, the
cellular and molecular mechanisms that regulate different as-
pects of human sepsis pathogenesis still remain poorly under-
stood. Moreover, the failure of numerous human clinical trials
as opposed to mice preclinical studies in sepsis also emphasize
the divergence in the immune mechanisms between these spe-
cies as reported recently. These facts further reinforce the imme-
diate necessity for investigating sepsis and its effects in humans.
Monocytes and macrophages are believed to play an im-
portant role in orchestrating the host immune response during
sepsis (Biswas and Lopez-Collazo, 2009). They can potentially
participate in both phases of sepsis by releasing inflammatory
cytokines that contribute to ‘‘cytokine storm’’ and ultimately
adopting an immunosuppressive phenotype whereupon they
are unable to respond to secondary infections. However,
whether monocytes and macrophages can actually perform
such diverse functions to contribute to the pathogenesis of
sepsis in humans needs investigation. A better definition of
how the gene expression and functional activities of monocyte
and macrophage are regulated in human sepsis patients can
provide valuable insight into fundamental disease mechanisms
and their possible therapeutic targeting.
In the current study, we have applied a combination of tran-
scriptomic and functional approaches to immune profile blood
monocytes during Gram-negative sepsis in adults, including
follow-on analyses of the same individuals after sepsis resolution,
to clarify how thesecells contribute toprogression of thedisorder.
We demonstrate that bloodmonocytes from patients displayed a
functional plasticity, transiting from a pro-inflammatory to an
immunosuppressive state during sepsis, and identify hypoxia
inducible factor-1a (HIF1a) as a keymediator ofmonocyte re-pro-
grammingunder theseconditions.Ourdata sheds lighton themo-
lecular and cellular basis of human sepsis progression that might
inform the development of targeted therapeutic interventions.
RESULTS
Monocytes from Sepsis Patients Exhibit a Distinct
Genetic Signature
Blood monocytes are believed to be major players in the dysre-
gulated inflammatory response during sepsis and characterizing
their response during this pathology provides insight into the
disease mechanism (Biswas and Lopez-Collazo, 2009). We
performed a transcriptomic characterization of human blood
monocytes isolated from patients during Gram-negative sepsis
(Sepsis-Monocytes) and following their resolution or recovery
(Recovery-Monocytes); monocytes from healthy donors (Mono-
cytes) were used as an additional baseline control population.
Hierarchical clustering of the monocyte transcriptomes showed
a clear segregation of the two populations, Sepsis-Monocytes
versus Recovery-Monocytes, indicative of their distinct gene
expression profiles (Figure 1A). However, Recovery-Monocytes
clustered closely with the control Monocytes suggesting that
their gene-expression profile represented a return toward the
baseline condition.
The transcriptome analysis of Sepsis-Monocytes identified
1,170 (561, upregulated; 609, downregulated) differentially ex-
pressed genes in Sepsis-Monocytes compared to Recovery-
Monocytes. Gene Ontology (GO) analysis was performed to
assess the biological processes related to these differentially ex-
pressed genes as shown in Figure S1. The top ten statistically
significant GO categories showed a prominence of essentially
immune response-related processes as shown in Figures S1A
and S1B and Figure 1B. In particular, immune response pro-
cessesmostly related to the upregulated differentially expressed
genes, whereas metabolic processes related to the downregu-
lated differentially expressed genes (Figures S1B and S1C).
Because we were interested in characterizing the immune
response of monocytes in sepsis, we focused on the im-mune-related differentially expressed genes in Sepsis-Mono-
cytes. The heatmap in Figure 1C shows that Sepsis-Monocytes
upregulate a large number of immune-related genes encoding
cytokines, chemokines, surface molecules, and transcription
factors. Many of these cytokine and chemokine genes were
also validated by qPCR array (Figure 1D). Analysis of Sepsis-
Monocytes culture supernatants confirmed the significant
upregulation of pro-inflammatory cytokines and chemokines
including interlekin-1b (IL-1b), IL-6, and the chemokines CCL3
and CCL5, as compared to Recovery-Monocytes (Figure 1E).
The anti-inflammatory cytokine, IL-10 was also found to be up-
regulated alongside pro-inflammatory cytokines and chemo-
kines in the Sepsis-Monocytes. Consistent with these observa-
tions, NF-kB, a central transcriptional regulator of inflammatory
response, was found to be activated in the Sepsis-Monocytes,
as indicated by the heightened expression of phospho-IkBa
(Figure 1F). Figure 1G presents a diagrammatic overview of
some key immune-related genes modulated in Sepsis-Mono-
cytes, indicating a gene-expression profile that is consistent
with monocyte activation and inflammation during ongoing
sepsis.
Blood Monocytes Display Altered Responses to
Endotoxin in Sepsis Patients
The high risk of fatal secondary infections in sepsis is thought to
be due to the immunosuppressive state of blood leukocytes in
these patients (Boomer et al., 2011; Hotchkiss et al., 2009). We
therefore sought to determine whether human blood monocytes
displayed an altered response to endotoxin challenge in ongoing
sepsis. To have a global view of this phenomenon, the response
of Sepsis- and Recovery-Monocytes to ex vivo lipopolysaccha-
ride (LPS) challenge was compared using microarray. Hierarchi-
cal clustering in Figure 2A showed a clear segregation of
LPS-treated Recovery-Monocytes from their untreated counter-
parts (i.e., Recovery-Monocytes+LPS versus Recovery-Mono-
cytes) suggesting a distinct transcriptomic response to LPS
in these cells. In contrast, LPS-treated Sepsis-Monocytes did
not segregate from their untreated counterpart (i.e., Sepsis-
Monocytes+LPS versus Sepsis-Monocytes), indicating the fail-
ure to display a distinct transcriptomic response to LPS. The
defective LPS response of Sepsis-Monocytes was also evident
quantitatively by the markedly lesser number of differentially ex-
pressed genes (76) compared to Recovery-Monocytes (2,221
genes), in response to LPS (Figure 2B).
We further analyzed the LPS response of Sepsis- versus Re-
covery-Monocytes. Upregulation of inflammatory cytokine and
chemokine genes is a key feature of LPS response in myelomo-
nocytic cells (Schroder et al., 2012). Accordingly, we foundmany
cytokines (e.g., tumor necrosis factor [TNF], IL1A, IL1B, IL6,
IL12A, IL23A) and chemokines (e.g., CCL3, CCL4, CCL5,
CCL20, CCL23, CXCL2, CXCL11) to be upregulated in the
LPS transcriptome of Recovery-Monocytes, but not in that of
Sepsis-Monocytes, indicating a defect in the LPS-induced in-
flammatory response of Sepsis-Monocytes (Figure 2C). A similar
defect was also noted for the expression of genes encoding
several surface molecules (e.g., CD80, CD44) and transcription
factors (e.g., ATF5, NFKB1, NFKB2, REL, RELA) related to im-
mune activation (Figure 2C, compare Sepsis- with Recovery-
Monocytes). Figure 2D shows a diagrammatic overview ofImmunity 42, 484–498, March 17, 2015 ª2015 Elsevier Inc. 485
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Figure 1. Transcriptome Profiling of Monocytes from Sepsis Patients
(A) Hierarchical clustering with Pearson’s correlation and complete linkage of Sepsis-Monocytes (n = 7), Recovery-Monocytes (n = 7) and healthy donor
Monocytes (n = 5).
(B) Gene Ontology (GO) classification of differentially expressed genes showing immune-related biological functions.
(C) Heatmap showing differential expression of genes belonging to cytokines, chemokines, selected surface molecules, and transcription factors in Sepsis-
versus Recovery-Monocytes. Monocytes are shown as an additional baseline control population. Differentially expressed genes determined by Limma and row-
based Z score were normalized.
(legend continued on next page)
486 Immunity 42, 484–498, March 17, 2015 ª2015 Elsevier Inc.
the gene-expression data indicating impaired inflammatory
response of Sepsis-Monocytes in response to LPS.
Distinct from the large number of immune-related genes (422)
that showed downregulation in the LPS-treated Sepsis-Mono-
cytes, an equal number of genes (504) were found to be still
inducible or less repressed in the Sepsis-Monocytes than Re-
covery-Monocytes, in response to LPS treatment. GO analysis
of these genes mapped them to miscellaneous functions
including metabolism and phagocytosis-related processes (Fig-
ure S2). The anti-microbial gene HAMP also fell in the latter cate-
gory and is investigated later in this study. Overall, these data
indicate a profound gene ‘‘re-programming’’ in Sepsis-Mono-
cytes associated with their altered response to LPS.
Monocytes Exhibit Hallmarks of Endotoxin Tolerance
In Vivo in Human Sepsis
Given the altered transcriptomic response of monocytes to
LPS in sepsis, we next investigated whether key monocyte func-
tions were also disrupted under these conditions. Compared
to Recovery-Monocytes, Sepsis-Monocytes exhibited a marked
reduction in LPS-induced pro-inflammatory genes including
CCL3, 4, 5; CXCL2, 11; IL1A, IL1B, IL6, and TNF, by qPCR
(Figure 3A), that mirrored our transcriptome data (Figure 2C).
Reduced expression of some of these cytokines and chemo-
kines was also confirmed in the culture supernatants of LPS-
treated Sepsis-Monocytes (Figure 3B). Thus, Sepsis-Monocytes
exhibit an attenuated inflammatory response to LPS. Consistent
with this, LPS-treated Sepsis-Monocytes also showed reduced
phospho-IkBa expression, indicating an impaired activation of
NF-kB, the key transcriptional regulator of inflammatory res-
ponse (Figure 3C).
We next assessed the antigen-presenting function of Sepsis-
Monocytes, because it is essential for immune activation and a
sustained host immune response. Sepsis-Monocytes showed
decreased expression of several key co-stimulatory and major
histocompatibility complex class II (MHCII) molecule genes
(CD80, CD40, and HLA-DOB) upon LPS treatment (Figure 3D),
suggesting that the antigen-presenting ability of these cells
might be impaired. Indeed, a mixed lymphocyte reaction (MLR)
revealed LPS-treated Sepsis-Monocytes to induce a signifi-
cantly lower T cell proliferation than Recovery-Monocytes coun-
terpart (Figure 3E).
Monocytes and macrophages also mediated direct killing of
pathogens via phagocytosis. Figure 3F shows Sepsis-Mono-
cytes displayed a higher phagocytotic ability than control mono-
cytes (Monocytes). Supernatants of Sepsis-Monocytes also
demonstrated heightened ability to restrict growth of bacteria
(E. coli) (Figure 3G). In line with this observation, Sepsis-Mono-
cytes displayed enhanced expression of the anti-microbial
gene HAMP upon LPS stimulation (Figure 3H).
Defective cytokine release in response to LPS, impaired anti-
gen presenting function, and increased expression of anti-micro-(D) qPCR of indicated genes in Sepsis- versus Recovery-Monocytes.
(E) Cytokine expression in culture supernatants of Sepsis- versus Recovery-Mon
(F) Phospho-IkBa expression in Sepsis- versus Recovery-Monocytes. Values are
(G) Diagrammatic overview of Sepsis-Monocytes showing selected immune-rela
represents upregulated; green represents downregulated; Panels showing transc
See also Figure S1.bial genes are features reported for in vitro endotoxin tolerance
(Biswas and Lopez-Collazo, 2009; del Fresno et al., 2009; Foster
et al., 2007). Therefore, the present observations on Sepsis-
Monocytes strongly suggest them to be conditioned to a refrac-
tory or endotoxin tolerant phenotype in vivo during sepsis.
Sepsis-Monocytes Upregulate Tissue Re-modeling
Functions
Acute inflammation during sepsis often involves tissue damage,
which must be repaired to protect the host. Monocytes and
macrophages release matrix metalloproteases (MMPs) and
angiogenic factors such as vascular endothelial growth factors
(e.g., VEGFA) and are known to contribute to tissue re-modeling
and wound healing (Murray and Wynn, 2011). The heatmap
in Figure 4A shows increased expression of several MMP genes
in Sepsis-Monocytes compared to Recovery-Monocytes. qPCR
confirmed increased MMP9 and MMP19 expression in the
Sepsis-Monocytes (Figure 4B). MMP activity was confirmed
using zymography, which showed increased gelatinase activity
in the supernatants of Sepsis-Monocytes (Figure 4C). Functional
consequence of this heightened MMP activity was demon-
strated by the increased ability of Sepsis-Monocyte superna-
tants to stimulate re-epithelialization of wounded human fibro-
blasts (wound healing), as compared to Recovery-Monocyte
(Figure 4D). Marked inhibition of this phenomenon using a
pan-MMP inhibitor confirmed MMPs to mediate this event
(Figure 4D).
Sepsis-Monocytes also exhibited marked upregulation of
vascular endothelial growth factor-A (VEGFA) gene expression
and release, compared to Recovery-Monocytes (Figures 4E
and 4F). Increased VEGFA expression correlated with a signifi-
cantly heightened human umbilical vein endothelial cell (HUVEC)
tube formation by Sepsis-Monocyte supernatants, indicating
their enhanced angiogenic activity (Figure 4G). This was medi-
ated through VEGF as demonstrated by the ability of VEGFR2
blocking antibody to markedly inhibit this process (Figure 4G).
Collectively, our above data indicate enhanced tissue re-
modeling functions of Sepsis-Monocytes as compared to
Recovery-Monocytes.
HIF1a Expression and Activation Influence the
Gene-Expression Profile of Sepsis-Monocytes
We investigated the potential mechanism(s) that might control
the transcriptional and functional re-programming of mono-
cytes during sepsis. The transcription factor, hypoxia induc-
ible factor-1a (HIF1a) regulates mammalian cell response to
hypoxia (low oxygen concentration) and is induced by Gram-
negative endotoxin challenge in mice (Rius et al., 2008). Our
microarray data indicated that HIF1A was differentially upre-
gulated in Sepsis-Monocytes compared to Recovery-Mono-
cytes (Figure 1C), also confirmed by increased HIF1A (not
HIF2A) expression by qPCR and HIF1a binding assay (Figuresocytes.
mean ± SEM (D and F: n = 3; E: n = 4), *p < 0.05 versus Recovery-Monocytes.
ted differentially expressed genes as compared to Recovery-Monocytes. Red
riptome analysis represent data from the number of subjects as indicated in (A).
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Figure 2. Blood Monocytes Display Altered Responses to Endotoxin in Sepsis Patients
(A) Hierarchical clustering with Pearson’s correlation and complete linkage of Sepsis-Monocytes (n = 7), Recovery-Monocytes (n = 7), and healthy donor
Monocytes (n = 2) in response to ex vivo LPS treatment (3 hr).
(B) Total number of LPS-induced differentially expressed genes in Sepsis- and Recovery-Monocytes. Box indicates the total number of differentially expressed
genes.
(C) Heatmaps showing the differential modulation of indicated genes in Recovery- versus Sepsis-Monocytes, in response to LPS.
(legend continued on next page)
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Figure 3. Monocytes Exhibit Hallmarks of
Endotoxin Tolerance In Vivo in Human
Sepsis
(A) qPCR of indicated genes in Sepsis- versus
Recovery-Monocytes, upon LPS stimulation (3 hr).
(B) Indicated cytokine and chemokine expression
in culture supernatants of Sepsis- and Recovery-
Monocytes, upon LPS treatment (12 hr).
(C) Phospho-IkBa expression in response to LPS
in Sepsis- versus Recovery-Monocytes, *p < 0.05
versus Recovery-Monocytes+LPS.
(D) qPCR of indicated genes in Sepsis- and Re-
covery-Monocytes upon LPS challenge.
(E) MLR assay showing proliferation of T cells from
healthy donors upon incubation with LPS-treated
Sepsis- or Recovery-Monocytes, *p < 0.05 versus
Recovery-Monocytes+LPS.
(F) Ability of Sepsis- versus Control-Monocytes
(Monocytes) to phagocytosize GFP-labeled
E. coli, *p < 0.05 versus control Monocytes.
(G) Anti-microbial activity of supernatants from
Sepsis- or Recovery-Mo showing inhibition of
E. coli growth (dark area, see arrow), on agar
plates. Each spot represents the supernatant from
a particular subject.
(H) qPCR of anti-microbial gene HAMP in Sepsis-
or Recovery-Mo following LPS stimulation. Values
in all panels aremean ±SEM (A, C, D, H: n = 3; B, F,
G: n = 4; E: n = 5).5A and 5B). Indeed, a gene set enrichment analysis (GSEA)
revealed enrichment of hypoxia-inducible genes in the
Sepsis-Monocyte transcriptome (Figure 5C). Further, hypoxia
is reported to upregulate IRAKM (or IRAK3), a negative regu-(D) Diagrammatic overview of the impaired LPS response of Sepsis-Monocytes. Expression of selected
Monocytes in response to LPS is indicated. Gene expression in response to LPS is presented relative to the
color coding indicates varying expression of genes that are differentially induced by LPS. Grey indicates gene
data in (B)–(D) are from n = 7 patients during Sepsis and Recovery, respectively. See also Figure S2.
Immunity 42, 484–49lator of Toll-like receptor (TLR) signaling
(Bosco et al., 2006; Fang et al., 2009;
Kobayashi et al., 2002; Lo´pez-Collazo
et al., 2006). We therefore checked the
expression of this gene in Sepsis-
Monocytes and confirmed its upregula-
tion by qPCR (Figure 5D).
Taken together, the upregulation of
HIF1a and enrichment of hypoxia in-
ducible genes in Sepsis-Monocytes sug-
gested the involvement of this transcrip-
tion factor in the regulation of monocyte
response in sepsis, which was further
investigated.
HIF1a Is a Regulator of IRAKM
Expression in Monocytes
IRAKM is one of the few conserved nega-
tive regulators of TLR pathway in mice
and humans (van ’t Veer et al., 2007),
and is implicated in endotoxin tolerance(Kobayashi et al., 2002). Hence, the upregulation of IRAKM in
Sepsis-Monocytes (Figure 5D) is consistent with their impaired
LPS response and endotoxin tolerant phenotype, as shown
earlier (Figure 3). However, the mechanism by which IRAKM isimmune-related genes in Sepsis- and Recovery-
respective non-LPS treated counterpart. Red-pink
s not differentially induced by LPS. Transcriptome
8, March 17, 2015 ª2015 Elsevier Inc. 489
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Figure 4. Sepsis-Monocytes ShowElevated
Tissue Remodeling Functions
(A) Heatmap showing MMP gene modulation in
Recovery- versus Sepsis-Monocytes (n = 7).
(B) qPCR for MMP9 and MMP19 in Sepsis- and
Recovery-Mo.
(C) Zymography assay showing MMP(gelatinase)
activity in culture supernatants of Sepsis- and
Recovery-Monocytes.
(D) Wound-healing assay showing percent healing
of wounded fibroblasts incubated with superna-
tant of Sepsis- or Recovery-Monocytes. Quantifi-
cation and picture of wound healing (closure) is
shown. Dotted line represents wound margin.
Scale bar represents 0.5 mm. Wound healing in
presence of a vehicle control (Veh) or MMP in-
hibitor is also shown. Data are representative of
two independent experiments.
(E) VEGFA gene expression and (F) release by
Sepsis- and Recovery-Monocytes.
(G) Enhanced angiogenesis (HUVEC tube forma-
tion) induced by supernatants of Sepsis-Mono-
cytes. Quantification and pictures are shown.
Scale bar represents 0.1 mm. The effect of
VEGFR2 antibody or its isotype control (Iso Ab) on
tube formation is also shown. Data are represen-
tative of two independent experiments; Values
in all panels are mean ± SEM (B, E: n = 3; D, F, G:
n = 4), *p < 0.05 versus Recovery-Monocytes.induced and regulated in these cells is not known. Based on Fig-
ure 5, we decided to investigate whether HIF1a regulates the
expression of IRAKM in response to endotoxin. IRAKM expres-
sion was assessed in human monocytes treated with CoCl2, an
activator of HIF1 (Huang et al., 2003). CoCl2-treated monocytes
upregulated IRAKM gene expression and protein, indicating the490 Immunity 42, 484–498, March 17, 2015 ª2015 Elsevier Inc.regulatory role of HIF1 (Figures 6A and
6B); concurrent upregulation of VEGFA
and HIF1A served as positive controls.
Similar results were also obtained in
hypoxia-stimulated cells (Figure S3A).
Because the sepsis condition is linked
to persistent exposure to endotoxins,
we next checked whether HIF1 activa-
tion combined with endotoxin exposure
could augment monocyte expression of
IRAKM. For this purpose, monocytes
were treated with or without CoCl2 for
12 hr and thereafter challenged with Lipid
A (LPA, a key component of gram-nega-
tive endotoxins and a specific TLR4
ligand) for 4 hr and assessed for IRAKM
expression. CoCl2+LPA treatment signif-
icantly increased expression of IRAKM,
VEGFA, and HIF1A, as compared to
monocytes treated with LPA alone
(Figure 6C).
To directly demonstrate that HIF1awas
responsible for inducing IRAKM expres-
sion in LPA-treated monocytes, we over-
expressed HIF1a in monocytes and stud-ied their response to LPA. Monocytes transfected with a HIF1a
plasmid markedly upregulated IRAKM (and HIF1A) compared to
control plasmid transfectedcells, uponLPAchallenge (Figure6D).
We also performed HIF1a small interfering RNA (siRNA)-silencing
experiments in monocytes. LPA alone could induce HIF1A
expression in monocytes (Figure S3B). However, LPA stimulation
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Figure 5. Sepsis-Monocytes Express Hypoxia-Inducible Genes
(A and B) HIF1a gene expression and binding assay in Sepsis- and Recovery-
Monocytes.
(C) GSEA was performed between normoxia versus hypoxia datasets (from
GEO and ArrayExpress) and our Sepsis- versus Recovery-Monocytes dataset.
A positive score indicates positive gene enrichment between the hypoxia-
inducible genes and Sepsis differentially expressed genes.
(D) Upregulated IRAKM gene expression in Sepsis-Monocytes. Values in (A),
(B), and (D) are mean ± SEM (n = 3), *p < 0.05 versus Recovery-Mo.of siHIF1a-silenced monocytes showed a significant decrease in
the expression of IRAKM (as well as VEGFA and HIF1A) as
compared to their control siRNA-treatedcounterparts, implicating
HIF1a in mediating LPA-induced IRAKM expression (Figure 6E).
Taken together, the results from the above approaches, i.e.,
pharmacological activation (via CoCl2), overexpression, and
silencing of HIF1a, clearly establish HIF1a as an important regu-
lator of IRAKM expression in human monocytes.
Additional support to the above findings also came frommeta-
analysis of GEO-deposited datasets of sepsis patients wherein
a statistically significant upregulation and correlation between
HIF1A and IRAKM was observed in three independent patient
cohorts as compared to their respective control population (Fig-
ures S3C–S3D).
HIF1a-Induced Upregulation of IRAKM Skews Monocyte
Pro-inflammatory Function
Although our results demonstrated HIF1a to regulate IRAKM
expression inmonocytes in response to LPA, wewondered about
the functional consequenceof this phenomenon. Because IRAKM
isa negative regulator of TLRpathway, it is conceivable that its up-
regulation (via HIF1a) should concomitantly inhibit LPA-induced
pro-inflammatory response. To demonstrate this, we assessed
the expression of pro-inflammatory cytokines and chemokinesin all the experiments described above. Concomitant with the up-
regulationof IRAKMinCoCl2+LPA-treatedmonocytes (Figure6C),
their expression of pro-inflammatory cytokine and chemokine
genes like TNF, IL6, and CCL5 was attenuated as compared
to monocytes treated with LPA alone (Figure 6F). However, this
attenuation was only visible in monocytes pre-treated with
CoCl2 for 12 hr but not 4 hr, possibly suggesting thatHIF1a activa-
tion at late time pointsmediated this effect (Figure S3E). Decrease
in the corresponding cytokines was also detected by ELISA
(Figure S3F). Further, we silenced IRAKM in these monocytes.
Figure S3G, shows monocytes treated with IRAKM siRNA failed
to repress the pro-inflammatory genes upon treatment with
CoCl2+LPA, directly implicating IRAKM inmediating the suppres-
sion of pro-inflammatory gene expression.
Mirroring the results of Figure 6F, HIF1a overexpression also
showed a marked downregulation of LPA-induced pro-inflam-
matory cytokines (Figure 6G, Figure S3H). Taken together, the
results from Figures 6C–6G clearly demonstrate that HIF1a, by
inducing IRAKM expression in human monocytes, attenuates
their pro-inflammatory response to endotoxin challenge.
To further demonstrate the functional impact of this attenu-
ated pro-inflammatory response of monocytes, we also looked
at the ability of these cells to polarize T cells. CoCl2+LPA-treated
monocytes showed downregulation of co-stimulatory molecule
genes like CD80 and CD40 (Figure 6H). Testing their ability to
polarize T cells revealed CoCl2+LPA-treated monocytes to in-
crease polarization to T regulatory (Tregs) cells (Figure 6I). This
is in line with the decreased IL-6 (Figure 6F, Figure S3F) and
increased TGF-b gene expression (Figure 6J) by these cells,
the two key determinants for Treg cell polarization (Kimura and
Kishimoto, 2010).
Collectively, the results presented in Figure 6 demonstrate that
HIF1a (via IRAKM upregulation) functionally re-programs mono-
cytes to an immunosuppressive phenotype characterized by a
defective pro-inflammatory response to endotoxin and skewing
of T cells to Treg cells. This immunosuppressive phenotype is
reminiscent of the phenotype we observed in the Sepsis-Mono-
cytes and in in vitro endotoxin tolerance.
HIF1a Upregulates Tissue Re-Modeling and Anti-
microbial Functions of Monocytes
Since our earlier results showed sepsis monocytes to upregulate
tissue re-modeling and anti-microbial functions (Figure 3 and 4),
we next checked whether HIF1a regulated these functions and
their genes (e.g., MMP9, MMP19, VEGFA, HAMP) in response
to endotoxin. As shown in Figure 7A, CoCl2+LPA-treated mono-
cytes showed a significant upregulation of MMP9 and MMP19
compare to LPA-treated monocytes, suggesting an involve-
ment of HIF1 in the regulation of these genes. Confirming this,
HIF1a overexpression also upregulated MMP9 and MMP19 in
response to LPA (Figure 7B). Conversely, HIF1a siRNA signifi-
cantly downregulated LPA-induced MMP9 and MMP19 in
monocytes (Figure 7C).
Consistentwith Figure 7A, at functional level, supernatants from
CoCl2+LPA-treated monocytes showed significantly heightened
wounded healing (Figure 7D). Inhibition of this event by a pan-
MMP inhibitor proved mediation through MMPs (Figure 7D).
Angiogenesis is an important aspect of tissue remodeling
that is upregulated by Sepsis-Monocytes. PharmacologicalImmunity 42, 484–498, March 17, 2015 ª2015 Elsevier Inc. 491
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Figure 6. HIF1a Induces the Expression of IRAKM that Skews Monocyte Pro-inflammatory Function
(A) qPCR of indicated genes in monocytes from healthy donors treated or not with CoCl2 (0.25mM) for 12 hr, *p < 0.05 versus Control.
(B) Immunoblot showing IRAKM expression in CoCl2-treatedmonocytes. Actin expression indicates loading control. Inset shows densitometry analysis; qPCR of
indicated genes in monocytes (C) treated or not with CoCl2 (12 hr) and then exposed to LPA (100ng/ml) for 4 hr, *p < 0.05 versus LPA.
(D) transfected with a control or HIF1a expressing plasmid following by LPA challenge (4 hr), *p < 0.05 versus Control+LPA.
(E) Treated with control or HIF1a siRNA and stimulated with LPA (4 hr), *p < 0.05 versus Control siRNA+LPA; qPCR analysis of indicated genes in monocytes (F)
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(legend continued on next page)
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Figure 7. HIF1a Upregulates Tissue Re-
modeling and Anti-microbial Functions of
Monocytes
(A) qPCR of indicated genes in monocytes treated
with LPA or CoCl2+LPA, *p < 0.05 versus LPA.
(B) qPCR of indicated genes in monocytes trans-
fected with control or HIF1a plasmid and stimu-
lated with LPA, *p < 0.05 versus Control+LPA.
(C) qPCR of indicated genes in monocytes treated
with control or HIF1a siRNA and stimulated with
LPA, *p < 0.05 versus Control siRNA+LPA.
(D) Wound-healing assay showing percent heal-
ing of wounded fibroblasts incubated with
supernatant of LPA or CoCl2+LPA treated
monocytes (n = 3), *p < 0.05 versus LPA. Wound
healing in presence of a vehicle control (Veh) or
MMP inhibitor is also shown. Data are repre-
sentative of two independent experiments.
Dotted lines represent wound margin. Scale bar
represents 0.5 mm.
(E) Angiogenesis assay enumerating HUVEC tube
formation induced by supernatants from LPA or
CoCl2+LPA treated monocytes (n = 3). The effect
of VEGFR2 antibody or its isotype control (Iso Ab)
on tube formation is also shown. Data are re-
presentative of two independent experiments.
Scale bar represents 0.1 mm; qPCR of HAMP
expression in monocytes (F) treated with LPA or
CoCl2+LPA,*p < 0.05 versus LPA.
(G) Transfected with control or HIF1a plasmid
following LPA stimulation, *p < 0.05 versus
Control+LPA.
(H) Treated with control or HIF1a siRNA following
LPA treatment, *p< 0.05 versusControl siRNA+LPA.
(I) Anti-microbial activity of the supernatants from
monocytes treated or not with CoCl2 showing in-
hibition of bacterial (E. coli) growth on agar plates,
as described in the legend for Figure 3G (n = 3).
Values in all panels are mean ± SEM (A, F, G: n = 4;
B, C, H: n = 3). See also Figure S4.activation (CoCl2) and genetic overexpression of HIF1a in mono-
cytes was mirrored by increased VEGFA, a key angiogenic and
well-known HIF1a target gene (Forsythe et al., 1996), whereas
HIF1a siRNA abrogated this effect (Figures 6C–6E). At a func-(I) Bar graph showing % of CD4+ T cells polarized toward Tregs (CD25+FOXP3+) in an MLR assay performe
CoCl2+LPA.
(J) qPCR showing TGF-b gene expression in LPA or CoCl2+LPA treatedmonocytes. Values in (A), (C)–(J) arem
See also Figure S3.
Immunity 42, 484–49tional level, supernatants from CoCl2+
LPA-treated monocytes markedly in-
crease angiogenic tube formation
compared to LPA-treated monocytes
(Figure 7E). Inhibition of this process by a
VEGFR2 blocking antibody demonstrates
mediation through VEGFA (Figure 7E).
Anti-microbial activity is another vital
function that is upregulated in Sepsis-
Mo. These cells also upregulated the
anti-microbial gene, HAMP. We show
here that activation of HIF1a by CoCl2 orits overexpression significantly upregulated HAMP in response
to LPA (Figures 7F and 7G). Conversely, HIF1a siRNA treatment
significantly downregulated HAMP (Figure 7H). At a functional
level, CoCl2-treated monocyte supernatants markedly restrictedd in the presence of monocytes treated with LPA or
ean ± SEM (A andC: n = 4; D–H: n = 3; I and J: n = 2).
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growth of E. coli bacteria, suggesting that HIF1 upregulates anti-
microbial activity (Figure 7I). Bacterial killing also involves the
generation of superoxides and phagocytosis. We showed that
CoCl2-treatedmonocytes increased their superoxide production
in response to LPA (Figure S4A). Similarly, overexpression of
HIF1a in monocytes upregulated their phagocytic ability toward
E. coli (Figure S4B).
In our biochemical studies on the regulation of tissue re-
modeling and anti-microbial genes by HIF1a, we noted these
genes to be upregulated only upon 12 hr, but not 4 hr, of CoCl2
pretreatment, suggesting that HIF1a activation at late rather than
early time point was responsible for this effect (Figure S4C).
Further, we also noted in the CoCl2+LPA-treated monocyte ex-
periments that silencing IRAKM in these cells did not affect the
expression these genes, suggesting these genes to be regulated
by HIF1a, independent of IRAKM (Figure S4D).
Taken together, our above results present multiple evidence
that establishes HIF1a as an important regulator of tissue re-
modeling and anti-microbial function in human monocytes.
However, these functions are regulated by HIF1a directly, inde-
pendent of IRAKM.
DISCUSSION
In the current report, we adopted a systems biology approach to
reveal that blood monocytes undergo phenotypic and functional
plasticity during the clinical course of Gram-negative sepsis in
humans. Circulating human monocytes displayed a pro-inflam-
matory gene-expression profile in ongoing sepsis. These same
cells also exhibited features of endotoxin tolerance such as
blunted inflammatory cytokine and chemokine production and
impaired antigen-presenting function when challenged with
LPS ex vivo. Mechanistically, upregulated expression of HIF1a
in blood monocytes mediated the expression of IRAKM, a nega-
tive regulator of TLR signaling, leading to the conversion of these
cells from a pro-inflammatory to an endotoxin-tolerant pheno-
type in sepsis. However, the capacity to phagocytosize bacteria,
express anti-microbial activity, and perform tissue re-modeling
or repair functions were increased in blood monocytes from
sepsis, indicating that monocyte function is re-configured rather
than globally suppressed under these conditions.
Transcriptome profiling of blood monocytes sampled from pa-
tients both during and after resolution of Gram-negative sepsis
revealed that a large number of pro-inflammatory cytokines, che-
mokines, and transcription factors were upregulated in mono-
cytes from sepsis patients (Sepsis-Monocytes) compared with
monocytes from the same subjects following resolution (Recov-
ery-Monocytes). These data are consistent with the concept
that blood monocytes (and likely tissue macrophages) directly
support the induction of a ‘‘cytokine storm’’ in response to sys-
temic bacterial infection in human sepsis. Supporting our tran-
scriptome data, identification of soluble factors secreted by
cultured Sepsis-Monocytes confirmed that blood monocytes
secrete increased pro-inflammatory cytokines and chemokines
including IL-1b, IL-6,CCL3,andCCL5 inongoingsepsis.Previous
microarrayanalysesofbloodmononuclear cells frompediatric, as
well as adult sepsis patients, have indicated the differential regu-
lation of several cytokine and chemokine genes such as IL1, IL8,
CCL3, andCCL4 (Pachot et al., 2006; Standage andWong, 2011;494 Immunity 42, 484–498, March 17, 2015 ª2015 Elsevier Inc.Tang et al., 2010). The objective of many of these studies was to
identify a predictive gene signature or biomarker(s) for sepsis
and its prognosis by comparing patients with healthy controls or
between cohorts with different clinical symptoms or outcomes.
However, identifying such biomarkers has been challenging due
to thewide rangeof etiologies associatedwith sepsis. In contrast,
our present study examined a well-defined population of sepsis
patients, i.e., Gram-negative sepsis patients. In these patients,
we examined the cellular and molecular basis of the aberrant
immune response in sepsis, pinpointing monocytes as a key
mediator of this response in humans. The importance of this cell
population is heightened because apoptosis of a large number
of immune subsets like lymphocytes and dendritic cells, but not
blood monocytes or interstitial macrophages, has been reported
in sepsis (Hotchkiss et al., 2013). Thus, characterizing Sepsis-
Monocytes provides a snapshot of the immune-inflammatory
response linked to sepsis. In addition, Sepsis-Monocytes also
modulated anti-microbial activity, tissue re-modeling, and meta-
bolism, suggesting other functions in sepsis.
Death in sepsis for most cases is not due to overt inflamma-
tion, which can be controlled by standard treatments such as
antibiotics and steroids, but instead reflects host immunosup-
pression that confers high risk of fatal nosocomial infection
(Hotchkiss et al., 2013). Indeed, post-mortem studies have
shown unresolved opportunistic infections in a large number of
patients dying of sepsis (Otto et al., 2011; Torgersen et al.,
2009). In contrast, other studies report the absence of active
infection in patients dying of sepsis and suggest the emerging
role of immunometabolism and neurophysiology in organ
dysfunction and death in sepsis (Deutschman and Tracey,
2014). It is likely that multiple events as mentioned above co-
exist and contribute to this phenomenon. Among these,
sepsis-related host immunosuppression has gained consider-
able attention recently (Hotchkiss et al., 2009; Hotchkiss et al.,
2013; Pachot et al., 2006). The mechanism(s) underlying such
immunosuppression (although not presently understood) might
be varied such as relative changes in the abundance of different
immune cell types (e.g., apoptosis of lymphocytes) (Hotchkiss
et al., 2013) or change in an individual immune cell type (e.g.,
altered response or function). In line with the latter, a potential
mechanism of immunosuppression in sepsis patients is the in-
duction of endotoxin tolerance, a process by which host immune
cells exposed to low doses of endotoxin over an extended period
become refractory to further endotoxin challenge (Adib-Conquy
and Cavaillon, 2009; Biswas and Lopez-Collazo, 2009). Studies
in murine macrophages and human monocytes have demon-
strated that endotoxin tolerance can be induced in vitro by pro-
longed exposure of these cells to low doses of LPS, leading to
downregulation of inflammatory cytokines TNF, IL-6, and IL-8,
and upregulation of the regulatory cytokine IL-10 (Biswas and
Lopez-Collazo, 2009; Foster et al., 2007; Medvedev et al.,
2000). Similar impairment in the production of TNF, IL-6, and
IL-1was also reported formonocytes from gram-negative sepsis
patients, upon ex vivo LPS challenge (Munoz et al., 1991). How-
ever, whether such an effect is restricted to a few genes or a
more wide-scale event is not well-understood. To clarify this,
we compared the LPS-stimulated transcriptome of Sepsis-
Monocytes with that of Recovery-Monocytes to identify an
impaired monocyte response to LPS during sepsis. These
findings together with qPCR results showed markedly reduced
gene expression of several pro-inflammatory cytokines or che-
mokines, inflammation-related transcription factors, and antigen
presentation-related molecules, corroborating with a downregu-
lation of monocyte activation. Our data provide transcriptomic
evidence confirming the in vivo endotoxin tolerance of human
blood monocytes in ongoing sepsis.
While the above observations conform to the general charac-
teristics of an endotoxin-tolerant phenotype in Sepsis-Mono-
cytes, several genes and functions related to anti-microbial
activity and tissue remodeling remain upregulated in these cells.
This suggests that monocytes undergo a transcriptomic and
functional ‘‘re-programming’’ in sepsis rather than a general sup-
pression of genes and functions. Supporting this, in vitro endo-
toxin tolerance studies in human monocytes and murine bone-
marrow-derived macrophages reported the downregulation of
inflammatory genes concomitant with increased expression of
anti-microbial genes in these cells (Biswas and Lopez-Collazo,
2009; del Fresno et al., 2009; Foster et al., 2007). In addition,
in vitro endotoxin tolerant human peripheral blood mononuclear
cells (PBMCs) and macrophages were recently shown to upre-
gulate genes related to wound healing (VEGFA, MMP9) and
phagocytosis (MARCO, CD23) (Pena et al., 2011), an observa-
tion supported in vivo by the upregulation of VEGFA, MMPs,
and heightened phagocytosis in Sepsis-Monocytes. Some
studies also link in vitro endotoxin tolerance to M2 macrophage
polarization, upregulating ARG1, YM1, and FIZZ1 genes in mice,
and CCL22, CCL24, CD163, and CD206 in humans (Pena et al.,
2011; Porta et al., 2009). Although our array data show CD163
upregulation in Sepsis-Monocytes, the fact that these cells
co-express pro-inflammatory signature together with immuno-
suppressive (e.g., impaired response to LPS ex vivo), tissue re-
modeling, and anti-microbial characteristics suggests a more
complex profile than a simple M1 or M2 polarization state. This
is conceivable considering the multitude of stimuli encountered
in vivo and the dynamic nature of the disease. In line with this
fact, a recent study reported that the immune response in
severely ill human patients exhibits both pro-inflammatory and
anti-inflammatory components that function in parallel (Xiao
et al., 2011). Similarly, another study profiling PBMCs from
sepsis patients also failed to demonstrate a distinctive pro- or
anti-inflammatory phase at the transcriptional level (Tang et al.,
2010), suggesting their co-existence, as proposed by others
(Adib-Conquy and Cavaillon, 2009). The phenotype of Sepsis-
Monocytes emerging from our study suggests a general adapta-
tion response to overt inflammation, which involves an impaired
capacity to support further inflammation and immune activation,
while promoting a protective response through an intact phago-
cytotic, anti-microbial, and tissue re-modeling functions.
Our transcriptomal and functional analyses of blood mono-
cytes demonstrates their in vivo functional re-programming in
course of human sepsis. Defining the mechanisms that support
monocyte functional plasticity or re-programming in human
sepsis is crucial in understanding the dysregulated host immune
response in sepsis progression. Several lines of evidence in the
current report suggest a mechanistic role for HIF1a in guiding
this functional re-programming of monocytes in human sepsis.
Using gene-enrichment analysis, we found that a large propor-
tion of the genes modulated in Sepsis-Monocytes were hypoxiainducible. Consistent with this fact, the expression and activity of
HIF-1a was found to be upregulated in Sepsis-Monocytes as
compared to Recovery-Monocytes. Further studies involving
the modulation of HIF1a using pharmacological, genetic overex-
pression and siRNA silencing approach established HIF1a to
regulate the expression of IRAKM, a well-known negative regu-
lator of the TLR signaling pathway and inducer of endotoxin
tolerance (Kobayashi et al., 2002; Lo´pez-Collazo et al., 2006).
Moreover, meta-analysis of sepsis leukocyte datasets showed
a significant correlation between increased HIF1A and IRAKM
expression in independent cohorts of sepsis patients. On the
basis of our results, we propose that during sepsis, exposure
to endotoxin triggers HIF1a activation in the monocytes, which
in turn induces IRAKM expression, thereby driving these cells
into an endotoxin-tolerant state. This correlates well with our ob-
servations on HIF1a activation, upregulation of IRAKM and the
endotoxin tolerant phenotype of Sepsis-Monocytes. In fact, we
could demonstrate that HIF1a not only upregulated IRAKM in
monocytes, but concomitantly downregulated the expression
of pro-inflammatory cytokines like TNF and IL-6 in response to
LPA, consistent with the negative regulatory role of IRAKM.
Indeed, using siIRAKM silencing in monocytes, we demon-
strated that IRAKM, downstream of HIF1a, was responsible for
mediating this downregulation of pro-inflammatory cytokines in
response to LPA. In contrast to these observations, earlier
studies in conditional genetically ablated mice have shown
HIF1a to support myeloid cell-mediated inflammation and pro-
inflammatory gene expression (Cramer et al., 2003; Nizet and
Johnson, 2009). Recently, HIF1a was also shown to mediate
IL-1b expression in LPS-treated macrophages (Tannahill et al.,
2013). The apparent paradox could perhaps be explained by
the fact that an initial HIF1a activation will induce a pro-inflam-
matory program in human monocytes, whereas chronic activa-
tion of this pathway (as occurs in sepsis) would lead to the
dampening of those same inflammatory responses via induction
of negative regulators such as IRAKM. Supporting such a view,
we showed that HIF1a activation (by CoCl2 treatment) at
late, but not early time points in monocytes suppressed their
pro-inflammatory cytokine expression in response to LPA.
Consistent with a role for HIF1a in ameliorating ongoing inflam-
mation, HIF1a was reported to increase the frequency and sup-
pressive properties of naturally occurring CD4+CD25+ regulatory
T cells (Ben-Shoshan et al., 2008). Tregs are increased in sepsis
(Hotchkiss et al., 2013). Supporting these observations, we
showed that HIF1a activation by CoCl2+LPA treatment in
monocytes increased their ability to induce Treg cell polarization.
This was possibly driven by the skewed IL-6 versus TGF-b
expression by monocytes, a hallmark for Treg cell polarization
(Kimura and Kishimoto, 2010). An immunosuppressive role for
HIF1a is also supported by studies in tumors, where HIF1a
was instrumental in polarizing tumor associated macrophages
to anM2-like phenotype and drivingmyeloid-derived suppressor
cells to their immunosuppressive phenotype (Colegio et al.,
2014; Corzo et al., 2010). In line with these, our finding
that HIF1a regulates IRAKM expression in monocytes identifies
a potential mechanism for targeting the immunosuppressive
response of monocytes in human sepsis.
In addition to the above data, we have presented biochemical
and genetic evidence demonstrating HIF1a to regulate tissueImmunity 42, 484–498, March 17, 2015 ª2015 Elsevier Inc. 495
remodeling and anti-microbial functions and their related genes
(e.g., VEGFA, MMP9, 19, and HAMP). However, HIF1a directly
regulated these independent of IRAKM. This is conceivable
because many of these molecules like VEGFA and MMPs
are target genes for HIF1a and hypoxia (Forsythe et al., 1996). In
line with our functional studies, mice studies have shown HIF1a
to mediate the anti-microbial activity in myeloid cells (Nizet and
Johnson, 2009). Taken together, ourmechanistic studies suggest
HIF1a as a crucial regulator of the functional plasticity of mono-
cytes during sepsis: regulating inflammatory response on one
hand and orchestrating protective responses on the other hand.
However, further studies on these different aspects of HIF1a in
humans would shed more light on the situation.
Although HIF1a regulates the expression of a diverse range of
genes (e.g., inflammatory, negative regulator, tissue remodeling,
and anti-microbial genes), it is pertinent to understand what
controls the target specificity and temporal regulation of such
HIF-induced genes. Recent studies indicate HIF to exert direct
or indirect transcriptional regulation involving other interacting
proteins, enhanceosomes, and epigenetic modifications (Scho¨-
del et al., 2011). While the relative contribution of these different
modes of HIF transcriptional regulation remains unclear, future
ChIP-Seq and epigenetic studies would clarify the extent of
such direct versus indirect regulatory effects of HIF1a on our
genes of interest (e.g., IRAKM, VEGFA, MMP gene), as well as
gene re-programming.
Another aspect of sepsis is its long-term effect on survivors.
Sepsis survivors have been reported to show significant
morbidity and mortality, with 5-year mortality rates of higher
than 70% (Deutschman and Tracey, 2014; Iwashyna et al.,
2010; Valde´s-Ferrer et al., 2013). Although the events underlying
such long-term effects remain unclear, elevated serum factors
like IL-6, HMGB1, and inflammatory monocytes have been sug-
gested in human and mice studies (Valde´s-Ferrer et al., 2013;
Yende et al., 2008). It is possible that persistence of such sub-
clinical inflammation might induce long-term and specific
changes in these immune cells that might contribute to the
altered status of these survivors. Although our study involved
sepsis survivors, its main focus was to characterize the immune
response of monocytes during sepsis (hence comparing Sepsis-
with Recovery-Monocytes), rather than post-sepsis susceptibil-
ity in these subjects. The latter is a different issue requiring future
investigation of the immune response in survivors at different
time points following recovery, in relation to healthy subjects.
In conclusion, using a systems biology approach, the present
study demonstrates that bloodmonocytes undergo aphenotypic
and functional re-programming during human sepsis that allows
these cells to transit froman inflammatory to an immunosuppres-
sive state, thereby contributing to both features of sepsis pro-
gression.Mechanistically, HIF1awas identified as a keymediator
of monocyte functional re-programming in sepsis, raising the
possibility of pharmacologically targeting this molecule tomodu-
late monocyte responses and human sepsis progression.EXPERIMENTAL PROCEDURES
Human Blood Samples
All access to blood samples from patients or healthy subjects were in compli-
ance with the guidelines approved by the local ethics committee. Further496 Immunity 42, 484–498, March 17, 2015 ª2015 Elsevier Inc.information on healthy and patient blood samples, as well as patient clinico-
pathological features, are provided in the Supplemental Experimental
Procedures.
qPCR Analysis
Cells were lysed in Trizol (Life Technologies, Invitrogen), and total RNA pre-
pared using the RNeasy kit (QIAGEN) as per manufacturer’s instructions. For
PCR Array analysis, total RNA was reverse transcribed using the RT2 First
Strand Kit (SABiosciences, QIAGEN). cDNA was utilized for qPCR using
PCR array plates for human inflammatory cytokines and their receptors
(SABiosciences, QIAGEN) and run on an iCycler iQ5 Real-Time PCR detection
system (Bio-Rad). Gene expression was analyzed using the manufacturer’s
analysis software (www.sabiosciences.com/pcrarraydataanalysis.php). For
normal qPCRs, total RNA was reverse transcribed using the Taqman reverse
transcription kit (Applied Biosystems) and cDNA ran for qPCR on iCycler iQ5
machine. Target gene expression was normalized to the expression of a
housekeeping gene, b-actin gene. Relative gene expression was calculated
using the standard 2-DDCt method.
siRNA Silencing and Overexpression Studies
RNA interference was performed using siRNAs targeted against human HIF1a
or IRAKM and compared with a control/scrambled siRNA (Invitrogen). Simi-
larly, HIF1a overexpression was performed by transfecting monocytes with
a human HIF1a expression plasmid or a control plasmid. Monocytes were nu-
cleoporated using Human Monocyte Nucleofector Kit (Amaxa Biosystems,
Lonza) in the presence of the respective siRNAs (20 nM) or plasmids (0.5 mg)
as per the manufacturer’s instructions. Overexpression or silencing was as-
sessed by qPCR analysis.
Bio-Plex Assays
Cell-free culture supernatants of human monocytes (50 ml) were assayed for
the presence of the indicated cytokines, chemokines, and growth factors
using the Bio-Plex Pro assay kit (Bio-Rad). For phospho-IkBa protein,
monocyte protein extracts were prepared and analyzed using the Bio-Plex
phospho-protein detection kit (Bio-Rad) as per the manufacturer’s instruc-
tions. All data were collected using the Bio-Plex 200 array system with
Luminex xMap Technology and analyzed using Bio-Plex Manager 6.0
(Bio-Rad).
ELISA
Cell-free culture supernatants of human monocytes were tested for TNF, IL-6,
and CCL5 using ELISA Kits (DuoSet Kits, R&D Systems) according to the man-
ufacturer’s instructions.
HIF1a Binding Assay
Monocytes from septic and recovered patients were processed and assayed
using the TransAMHIF1 kit (Active Motif) according to the manufacturer’s pro-
tocol. The optical density of the samples was quantified using an Infinite M200
plate reader (Tecan).
Statistical Analysis
Statistical significance was calculated by Student’s t test for comparisons be-
tween two groups, or by one-way ANOVA for comparisons of three or more
groups. p values < 0.05 were considered significant.
Additional methods including microarray and bioinformatics analysis, pa-
tient details, cell isolation and culture, and biochemical and functional assays
are provided in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The Gene Expression Omnibus (GEO) accession number for the microarray
data reported in this paper is GSE46955.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2015.02.001.
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